Lipella Pharmaceuticals Inc. LIPO

LIPO Company Overview

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet medical needs, particularly within urology and related inflammatory conditions. The company’s core mission is to advance novel drug formulations and delivery approaches aimed at improving outcomes in chronic and difficult-to-treat disorders of the bladder and urinary tract. As a development-stage enterprise, Lipella does not generate commercial product revenue and is primarily funded through equity financing and public market activity.

The company’s lead development efforts center on treatments for hemorrhagic cystitis and interstitial cystitis/bladder pain syndrome (IC/BPS), conditions for which approved therapeutic options are limited. Lipella’s strategy emphasizes reformulation of known active pharmaceutical ingredients using proprietary delivery technologies to enhance efficacy and safety. The company was founded in 2005, later transitioning into a publicly traded entity following its initial public offering in 2021, which provided capital to advance its clinical pipeline.